SOLTA MEDICAL INC 4
4 · SOLTA MEDICAL INC · Filed Jan 27, 2014
Insider Transaction Report
Form 4
Ferrari H Daniel
Vice President
Transactions
- Exercise/Conversion
Common Stock
2014-01-23+7,789→ 7,789 total - Exercise/Conversion
Common Stock
2014-01-23+14,906→ 14,906 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$1.92/sh−56,000$107,520→ 0 totalExercise: $1.00Exp: 2019-02-27→ Common Stock (56,000 underlying) - Disposition from Tender
Common Stock
2014-01-23$2.92/sh−194,643$568,358→ 0 total - Disposition from Tender
Common Stock
2014-01-23$2.92/sh−7,789$22,744→ 0 total - Disposition from Tender
Common Stock
2014-01-23$2.92/sh−14,906$43,526→ 0 total - Exercise/Conversion
Performance Restricted Stock Unit
2014-01-23−7,789→ 0 totalExp: 2022-02-08→ Common Stock (7,789 underlying) - Exercise/Conversion
Performance Restricted Stock Unit
2014-01-23−14,906→ 0 totalExp: 2023-02-04→ Common Stock (14,906 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$1.02/sh−8,000$8,160→ 0 totalExercise: $1.90Exp: 2016-03-13→ Common Stock (8,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$1.01/sh−100,000$101,000→ 0 totalExercise: $1.91Exp: 2020-02-08→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]Includes 2,500 shares acquired under the Issuer's 2006 Employee Stock Purchase Plan on January 21, 2014 and 105,499 shares deemed acquired pursuant to the grant of restricted stock units ("RSU's") on various dates. The vesting of the RSU's was accelerated in connection with the merger of the Issuer with Valeant Pharmaceuticals International, a Delaware corporation (the "Merger").
- [F2]Each performance right represented a contingent right to receive a share of Issuer common stock based on the Issuer's stock price performance. In connection with the Merger, the vesting (thus, the settlement) of the performance right was accelerated.
- [F3]This option, which had become fully vested and exercisable, was cancelled at the closing of the Merger in exchange for a cash payment equal to the product of (a) the number of shares underlying this option and (b) the difference between the merger consideration of $2.92 per share and the exercise price per share of this option.